Kraig Biocraft Laboratories Inc (KBLB): I cant wait to start worrying about tari...

I cant wait to start worrying about tariffs

igotthemojo · 2025-04-03T01:32:45.4770000Z

I cant wait to start worrying about tariffs on the many tons of product we will be producing…

Play Episode

8min

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Followers	81
Posts	22155
Boards Moderated	0
Alias Born	07/07/2006

Volume:	-
Day Range:
Bid:	0.0815
Ask:	0.086
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

KBLB Detailed Quote

Recent KBLB News

More KBLB News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent KBLB News

Go Ad-Free